

### **Overview**

### **Fund Objective**


ARKG is an actively managed Exchange Traded Fund (ETF) that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution.

### **Fund Description**

Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. The companies held in ARKG may be leaders, enablers, or beneficiaries of technologies including:


- → CRISPR
- → Targeted Therapeutics
- → Bioinformatics
- → Molecular Diagnostics





TICKER	ARKG
NET ASSETS	\$7,221 Million
ТҮРЕ	Active Equity ETF
CUSIP	00214Q302
ISIN	US00214Q3020
PRIMARY EXCHANGE	Cboe BZX
INCEPTION DATE	10/31/2014
EXPENSE RATIO	0.75%
TYPICAL NUMBER OF HOLDINGS	40-60






# **NAV Historical Change**

As of 11/30/2021







## **Performance**

### **ARKG Performance**

Annualized	d Cumulative		Calendar Year		
From: Quarter-End As of 09/30/2021					
ARKG	1 Year	3 Years	5 Years	Since Inception	
VAN	18.31%	33.40%	32.18%	22.25%	
Market Price	18.27%	33.32%	32.15%	22.25%	

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares when redeemed may be worth more or less than the original cost. Extraordinary performance is attributable in part due to unusually favorable market conditions and may not be repeated or consistently achieved in the future. The Fund's most recent month-end performance can be found in the fund material section. Returns for less than one year are not annualized. Net asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects the reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.




## **Top 10 Holdings**

**Full Holdings PDF** Full Holdings CSV As of 12/01/2021 **Market Value** Weight (%) **Ticker** Name **TDOC TELADOC HEALTH INC** \$419,562,180.00 7.59% **EXAS EXACT SCIENCES CORP** \$380,138,097.10 6.88% PACIFIC BIOSCIENCES OF CALIF \$313,966,799.41 **PACB** 5.68% FATE **FATE THERAPEUTICS INC** \$238,943,031.29 4.32% IONS **IONIS PHARMACEUTICALS INC** \$204,500,659.00 3.70% **VRTX VERTEX PHARMACEUTICALS INC** \$204,110,999.82 3.69% **TWST** TWIST BIOSCIENCE CORP \$196,679,098.50 3.56% \$191,973,311.88 **NTLA** INTELLIA THERAPEUTICS INC 3.47% **BEAM THERAPEUTICS INC** \$173,757,995.00 3.14% BEAM DNA **GINKGO BIOWORKS HOLDINGS INC** \$172,736,988.00 3.13%



# **Exposure Breakdowns**



Portfolio holdings and allocations are subject to change and should not be considered investment advice or a recommendation to buy, sell or hold any particular security.



#### **Know Your Fund**

## **Fund Documents**

#### **Featured Documents**



**Fact Sheet** 



**Summary Prospectus** 

 $\psi$ 



**Investment Case** 



Fund Holdings PDF  $\,^{\downarrow}$ 



Fund Holdings CSV  $\,\psi\,$ 

View All →

# **Premium/Discount**



# **Recent Premium/Discount**

#### As of 11/30/2021

NAV	4PM Mid-Point	Difference	Premium/Discount
\$63.52	\$63.46	-\$0.06	-0.09%





Select time period	4Q 2021 ▼
Historical Data	
Greatest Premium:	0.07% (10/26/2021)
Greatest Discount:	-0.11% (11/15/2021)
Number Of Days At	
Premium:	21
NAV:	6
Discount:	15
Days Within Percent Of NAV	
Percent Of Days ± 0.5% Of NAV:	100.00%
Number Of Days ± 0.5% Of NAV:	42

The Premium/Discount chart shows the difference between the daily market price of the Fund's shares and the Fund's net asset value ("NAV"). The daily market price is calculated using the mid-point between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00 pm Eastern time). The vertical axis of the chart shows the premium or discount of the Mid-Point price as a percentage of the NAV. The horizontal axis shows the number of trading days covered by the chart, and each bar in the chart demonstrates how many days the Fund traded within the



given premium/discount range. The data presented in the chart and table above represent past performance and cannot be used to predict future results.

\_

The principal risks of investing in ARKG include: Equity Securities Risk. The value of the equity securities the Fund holds may fall due to general market and economic conditions. Foreign Securities Risk. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. Health Care Sector Risk. The health care sector may be adversely affected by government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration of a patent may adversely affect their profitability. Biotechnology Company Risk. A biotechnology company's valuation can often be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities. Pharmaceutical Company Risk. Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Detailed information regarding the specific risks of ARKG can be found in the ETF's prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification risks, as well as fluctuations in market value and NAV. An investment in an ETF is subject to risks and you can lose money on your investment in an ETF. There can be no assurance that the ETF will achieve its investment objective. The ETF's portfolio is more volatile than broad market averages. Shares of ARKG are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.



The Adviser expects to invest at least 80% of the Fund's assets in Genomics Revolution Companies. However, certain of these companies do not currently derive a substantial portion of their current revenues from genomic-focused businesses and there is no assurance that any company will do so in the future, which may adversely affect the ability of the Fund to achieve its investment objective.

### **Explore Our ETFs**

ARK believes innovation is key to growth. Our ETFs aim to offer access to companies in some of the most promising areas of the



### **Help Center**

Investing in innovation starts with understanding it. Explore our Help Center to learn more and invest at

**Explore** →

**ARK ETF Trust** 

Active ETFs

Index ETFs

**Fund Resources** 

ARKK

IZRL

**Fund Documents** 



ARKQ PRNT Find Your Funds ARKW **CTRU ARK Trade Notifications** ARKG Help Center ARKF What are ETFs? **ARKX** Research Center Other Webinars About ARK The Switch (Videos) How To Invest Commentaries Subscribe To Updates Innovation Research

ARK ETF Trust © 2021 - 2026 Privacy Policy | Terms of Use

#### **DISCLOSURE**

Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ARK ETF before investing. This and other information are contained in the ARK ETFs' prospectuses, which may be obtained by clicking here. The prospectus should be read carefully before investing. An investment in an ARK ETF is subject to risks and you can lose money on your investment in an ARK ETF. There can be no assurance that the ARK ETFs will achieve their investment objectives. The ARK ETFs' portfolios are more volatile than broad market averages. The ARK ETFs also have specific risks, which are described in the ARK ETFs' prospectuses.

Shares of the ARK ETFs may be bought or sold throughout the day at their market price on the exchange on which they are listed. The market price of an ARK ETF's shares may be at, above or below the ARK ETF's net asset value ("NAV") and will fluctuate with changes in the NAV as well as supply and demand in



the market for the shares. The market price of ARK ETF shares may differ significantly from their NAV during periods of market volatility. Shares of the ARK ETFs may only be redeemed directly with the ARK ETFs at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ARK ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ARK ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns. Not FDIC Insured – No Bank Guarantee – May Lose Value

All statements made regarding companies, securities or other financial information on this site are strictly beliefs and points of view held by ARK Investment Management LLC and/or ARK ETF Trust and are subject to change without notice. Certain information on this site was obtained from sources that ARK believes to be reliable; however, ARK does not guarantee the accuracy or completeness of any information obtained from any third party. The information on this site is for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. The information on this site is general in nature and should not be considered legal or tax advice. An investor should consult a financial professional, an attorney, or tax professional regarding the investor's specific situation.

Certain hyperlinks or referenced websites on this site may, for your convenience, forward you to third parties' websites, which generally are recognized by their top level domain name. Any descriptions of, references to, or links to other products, publications or services do not constitute an endorsement, authorization, sponsorship or affiliation with ARK with respect to any linked site or its sponsor, unless expressly stated by ARK. Any such information, products or sites have not necessarily been reviewed by ARK and are provided or maintained by third parties over whom ARK exercises no control. ARK expressly disclaims any responsibility for the content, the accuracy of the information, and/or the quality of products or services provided by or advertised on these third-party sites. ARK reserves the right to terminate any hyperlink or hyperlinking program at any time.

ARK Investment Management LLC is the investment adviser to the ARK ETFs.

Foreside Fund Services, LLC, distributor.

© 2021. ARK ETF Trust. No part of this material may be reproduced in any form, or referred to in any other publication, without written permission.